The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Open accessAbstract
BACKGROUND: The full complement of DNA mutations that are responsible for the pathogenesis of acute myeloid leukemia (AML) is not yet known. METHODS: We used massively parallel DNA sequencing to obtain a very high level of coverage (approximately 98%) of a primary, cytogenetically normal, de novo genome for AML with minimal maturation (AML-M1) and a matched normal skin genome. RESULTS: We identified 12 acquired (somatic) mutations within the coding sequences of genes and 52 somatic point mutations in conserved or regulatory portions of the genome. All mutations appeared to be heterozygous and present in nearly all cells in the tumor sample. Four of the 64 mutations occurred in at least 1 additional AML sample in 188 samples that were tested. Mutations in NRAS and NPM1 had been identified previously in patients with AML, but two other mutations had not been identified. One of these mutations, in the IDH1 gene, was present in 15 of 187 additional AML genomes tested and was strongly associated with normal cytogenetic status; it was present in 13 of 80 cytogenetically normal samples (16%). The other was a nongenic mutation in a genomic region with regulatory potential and conservation in higher mammals; we detected it in one additional AML tumor. The AML genome that we sequenced contains approximately 750 point mutations, of which only a small fraction are likely to be relevant to pathogenesis. CONCLUSIONS: By comparing the sequences of tumor and skin genomes of a patient with AML-M1, we have identified recurring mutations that may be relevant for pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recurrent somatic point mutations in the genes coding for isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) are found in a wide variety of cancers, including glioblastoma multiforme (GBM) (Yan et al., 2009) and acute myeloid leukemia (AML) (Dang et al., 2016; Mardis et al., 2009).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Mardis et al., 2009
In the citing paper
“Mutations in human cytosolic isocitrate dehydrogenase I (IDH1) occur somatically in >70% of grade II-III gliomas and secondary glioblastomas, and in 8.5% of acute myeloid leukemias (AML)”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“These IDH1 R132 mutations were observed in 8.5% of AML patients studied, and a significantly higher percentage of mutation was observed in the subset of patients whose tumors lacked cytogenetic abnormalities”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“In an AML case with an IDH1 mutation that was sequenced in its entirety (Mardis et al., 2009), there were a relatively small total number of somatic, non-synonymous mutations.”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“IDH1/2 mutations have been identified in a range of tumor types, including solid tumors (e.g., gliomas and chondrosarcomas) and blood cancers like acute myelogenous leukemia (169, 170, 171).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [170]
In the citing paper
“the lack of evidence that 2HG was acting as a mutagen (Mardis et al., 2009)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Mardis et al., 2009
In the citing paper
“Genomic sequencing of gliomas (Parsons et al., 2008; Yan et al., 2009) and acute myelogenous leukemia (Mardis et al., 2009) identified mutations in two isoforms of NADP+-dependent isocitrate dehydrogenase (IDH1 and IDH2).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Mardis et al., 2009
In the citing paper
“the concentrations at which it accumulates under pathogenic conditions suggests HIF-1α stabilisation and impaired collagen biogenesis may contribute to tumorigenicity126-130.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [129]
In the citing paper
“Treatment of AML with targeted therapies is particularly promising due to the fact that AMLs have far fewer mutations than most other adult cancers, with an average of only 13 mutations (Mardis et al, 2009; Cancer Genome Atlas Research Network, 2013).”
From Unlocking the potential of retinoic acid in anticancer therapy (2014) · cites this paper as Mardis et al, 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Accurate whole human genome sequencing using reversible terminator chemistry
Bentley, D. R., Balasubramanian, S., Swerdlow, H. P., Smith, G. P., Milton, J., Brown, C. G., Hall, K. P., Evers, D. J., Barnes, C. L., Bignell, H. R., et al. (2008) · Nature · doi:10.1038/nature07517 · Cited by 3,684
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,625
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Mapping short DNA sequencing reads and calling variants using mapping quality scores
Li, H., Ruan, J., & Durbin, R. (2008) · Genome Research · doi:10.1101/gr.078212.108 · Cited by 2,638
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,594
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D. J., Dunford-Shore, B. H., McGrath, S. D., Hickenbotham, M. T., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,434
Self-citationPrognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Cited by
Sorted by citations
Items 701–800 of 1,003
Greif, P. A., Eck, S. H., Konstandin, N. P., Benet‐Pagès, A., Ksienzyk, B., Dufour, A., Vetter, A. T., Popp, H. D., Lorenz‐Depiereux, B., Meitinger, T., et al. (2011) · Leukemia · doi:10.1038/leu.2011.19 · Cited by 61
Navis, A. C., Niclou, S. P., Fack, F., Stieber, D., van Lith, S. A. M., Verrijp, K. N., Wright, A. J., Stauber, J., Tops, B. B. J., Otte‐Höller, I., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-18 · Cited by 61
Sulai, N. H., Jimma, T., Lasho, T. L., Finke, C. M., Knudson, R. A., McClure, R. F., Pardanani, A. D., & Tefferi, A. (2011) · Blood · doi:10.1182/blood.v118.21.1751.1751 · Cited by 61
Acute Myeloid Leukemia: Aging and Epigenetics
Zjablovskaja, P., & Florian, M. C. (2019) · Cancers · doi:10.3390/cancers12010103 · Cited by 61
Pusch, S., Sahm, F., Meyer, J., Mittelbronn, M. G. A., Hartmann, C. J., & von Deimling, A. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01127.x · Cited by 61
Machida, Y., Nakagawa, M., Matsunaga, H., Yamaguchi, M., Ogawara, Y., Shima, Y., Yamagata, K., Katsumoto, T., Hattori, A., Itoh, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1349 · Cited by 60
Wang, X., Chen, Z., Xu, J., Tang, S., An, N., Jiang, L., Zhang, Y., Zhang, S., Zhang, Q., Shen, Y., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00650-w · Cited by 60
Sehgal, A. R., Gimotty, P. A., Zhao, J., Hsu, J., Daber, R. D., Morrissette, J. D., Luger, S. M., Loren, A. W., & Carroll, M. P. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0327 · Cited by 60
Genetics of Myeloproliferative Neoplasms
Viny, A. D., & Levine, R. L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000013 · Cited by 60
Wang, Z., Liang, S., Lian, X., Liu, L., Zhao, S., Xuan, Q., Guo, L., Liu, H., Yang, Y., Dong, T., et al. (2015) · Scientific Reports · doi:10.1038/srep09301 · Cited by 60
Computational analysis of next generation sequencing data and its applications in clinical oncology
Wadapurkar, R. M., & Vyas, R. (2018) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2018.05.003 · Cited by 60
Transcription factor mutations as a cause of familial myeloid neoplasms
Churpek, J. E., & Bresnick, E. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120854 · Cited by 60
Epigenetic therapies in acute myeloid leukemia: where to from here?
Fennell, K. A., Bell, C. C., & Dawson, M. A. (2019) · Blood · doi:10.1182/blood.2019003262 · Cited by 60
Muto, T., Guillamot, M., Yeung, J., Fang, J., Bennett, J. R., Nadorp, B., Lasry, A., Zea-Redondo, L., Choi, K., Gong, Y., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2021.12.007 · Cited by 60
The evolving molecular genetic landscape in acute myeloid leukaemia
Sanders, M. A., & Valk, P. J. M. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32835d821c · Cited by 59
Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
Fleischmann, M., Schnetzke, U., Hochhaus, A., & Scholl, S. (2021) · Cancers · doi:10.3390/cancers13225722 · Cited by 59
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
Fruchtman, H., Avigan, Z. M., Waksal, J. A., Brennan, N., & Mascarenhas, J. O. (2024) · Leukemia · doi:10.1038/s41375-024-02246-2 · Cited by 59
Epigenetic alterations in hematopoietic malignancies
Chung, Y. R., Schatoff, E. M., & Abdel-Wahab, O. I. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1181-z · Cited by 59
Lopez, G. Y., Reitman, Z. J., Solomon, D. A., Waldman, T. A., Bigner, D. D., McLendon, R. E., Rosenberg, S. A., Samuels, Y., & Yan, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.06.125 · Cited by 59
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma
Dunn, G. P., Andronesi, O. C., & Cahill, D. P. (2013) · Neurosurgical FOCUS · doi:10.3171/2012.12.focus12355 · Cited by 59
Enhanced tumorigenicity by mitochondrial DNA mild mutations
Cruz‐Bermúdez, A., Vallejo, C. G., Vicente-Blanco, R. J., Gallardo, M. E., Fernández‐Moreno, M. Á., Quintanilla, M., & Garesse, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3698 · Cited by 59
The variety of leukemic stem cells in myeloid malignancy
Wiseman, D. H., Greystoke, B., & Somervaille, T. C. P. (2013) · Oncogene · doi:10.1038/onc.2013.269 · Cited by 59
Hypomethylating Agents as a Therapy for AML
Gardin, C., & Dombret, H. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0363-4 · Cited by 59
Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer
Sasanakietkul, T., Murtha, T. D., Javid, M., Korah, R. M., & Carling, T. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.05.022 · Cited by 59
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Heuser, M., Palmisiano, N. D., Mantzaris, I., Mims, A. S., Dinardo, C. D., Silverman, L. R., Wang, E. S., Fiedler, W., Baldus, C. D., Schwind, S., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0996-5 · Cited by 59
Ogawara, Y., Katsumoto, T., Aikawa, Y., Shima, Y., Kagiyama, Y., Soga, T., Matsunaga, H., Seki, T., Araki, K., & Kitabayashi, I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2200 · Cited by 58
Duncavage, E. J., & Tandon, B. (2015) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12361 · Cited by 58
Valencia, C. A., Rhodenizer, D., Bhide, S., Chin, E., Littlejohn, M. R., Keong, L. M., Rutkowski, A., Bönnemann, C. G., & Hegde, M. (2012) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.01.009 · Cited by 58
Xu, L. P., Gu, Z., Li, Y., Zhang, J.-L., Chang, C., Pan, C., Shi, J., Shen, Y., Chen, B., Wang, Y., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407688111 · Cited by 58
Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice
Chen, T. H.-P., Kambal, A., Krysiak, K., Walshauser, M. A., Raju, G., Tibbitts, J. F., & Walter, M. J. (2010) · Blood · doi:10.1182/blood-2010-06-293167 · Cited by 58
Self-citationWeichenhan, D., & Plass, C. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt348 · Cited by 58
Kuo, F. C., Mar, B. G., Lindsley, R. C., & Lindeman, N. I. (2017) · Blood · doi:10.1182/blood-2017-03-734533 · Cited by 58
Kizilors, A., Crisà, E., Lea, N. C., Passera, R., Mian, S. A., Anwar, J., Best, S., Nicolini, F. E., Ireland, R. M., Aldouri, M., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30027-4 · Cited by 58
Significance of NPM1 Gene Mutations in AML
Hindley, A., Catherwood, M. A., McMullin, M. F., & Mills, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810040 · Cited by 57
The Tricarboxylic Acid Cycle Metabolites for Cancer: Friend or Enemy
Wu, J., Liu, N., Chen, J., Tao, Q., Li, Q., Li, J., Chen, X., & Peng, C. (2024) · Research · doi:10.34133/research.0351 · Cited by 57
Ma, S., Jiang, B., Deng, W., Gu, Z.-K., Wu, F.-Z., Li, T., Xia, Y., Yang, H., Ye, D., Xiong, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3330 · Cited by 57
Integration of Next-Generation Sequencing Into Clinical Practice: Are We There Yet?
Kohlmann, A., Grossmann, V., & Haferlach, T. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.11.008 · Cited by 57
Alteration of cohesin genes in myeloid diseases
Rocquain, J., Gelsi‐Boyer, V., Adélaı̈de, J., Murati, A., Carbuccia, N., Vey, N., Birnbaum, D., Mozziconacci, J., & Chaffanet, M. (2010) · American Journal of Hematology · doi:10.1002/ajh.21798 · Cited by 57
Lessons from next-generation sequencing analysis in hematological malignancies
Braggio, E., Egan, J. B., Fonseca, R., & Stewart, A. K. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.26 · Cited by 57
Fernandes, M. S., Reddy, M. M., Croteau, N. J., Walz, C., Weisbach, H., Podar, K., Band, H., Carroll, M. P., Reiter, A., Larson, R. A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.106161 · Cited by 57
Adamia, S., Bar‐Natan, M., Haibe‐Kains, B., Pilarski, P. M., Bach, C., Pevzner, S. J., Calimeri, T., Avet‐Loiseau, H., Lodé, L., Verselis, S. J., et al. (2014) · Blood · doi:10.1182/blood-2013-02-481507 · Cited by 57
Abel, H., Duncavage, E. J., Becker, N., Armstrong, J. R., Magrini, V. J., & Pfeifer, J. D. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq528 · Cited by 57
Self-citationGenomic profiling of B-progenitor acute lymphoblastic leukemia
Mullighan, C. G. (2011) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2011.09.004 · Cited by 57
MacConaill, L. E., Hummelen, P. V., Meyerson, M. M., & Hahn, W. C. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0110 · Cited by 57
The genomic landscape of prostate cancer
Baca, S. C., & Garraway, L. A. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00069 · Cited by 57
Chen, E., Yang, F., He, H., Li, Q., Zhang, W., Xing, J., Zhu, Z., Jiang, J., Wang, H., Zhao, X., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0925-7 · Cited by 57
Kattih, B., Shirvani, A., Klement, P., Garrido, A. M., Gabdoulline, R. R., Liebich, A., Brandes, M., Chaturvedi, A., Seeger, T., Thol, F. R., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01043-x · Cited by 57
Khan, K. H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i35.12391 · Cited by 56
IDH Inhibitors in AML—Promise and Pitfalls
McMurry, H. S., Fletcher, L. B., & Traer, E. A. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00619-3 · Cited by 56
Oncometabolites at the crossroads of genetic, epigenetic and ecological alterations in cancer
Lanzetti, L. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01402-6 · Cited by 57
Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis.
Feng, J., Guo, X., Chen, Y., Wang, Z.-J., Cheng, Y.-P., & Tang, Y. (2012) · PubMed Central · Cited by 56
Self-citationPardanani, A. D., Patnaik, M. M., Lasho, T. L., Mai, M., Knudson, R. A., Finke, C. M., Ketterling, R. P., McClure, R. F., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.98 · Cited by 56
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms
Martinez-Aviles, L. M., Besses, C., Álvarez‐Larrán, A., Torres, E., Serrano, S., & Bellosillo, B. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1330-0 · Cited by 56
Genetics of Myelodysplastic Syndromes: New Insights
Graubert, T. A., & Walter, M. J. (2011) · Hematology · doi:10.1182/asheducation-2011.1.543 · Cited by 56
Self-citationTargeting Metabolic Changes in Cancer: Novel Therapeutic Approaches
Bobrovnikova-Marjon, E. V., & Hurov, J. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112344 · Cited by 56
Rozhok, A. I., Salstrom, J. L., & DeGregori, J. V. (2014) · Aging · doi:10.18632/aging.100707 · Cited by 56
The Role of Reprogrammed Glucose Metabolism in Cancer
Ediriweera, M. K., & Jayasena, S. (2023) · Metabolites · doi:10.3390/metabo13030345 · Cited by 55
Fathi, A. T., Kim, H. T., Soiffer, R. J., Levis, M. J., Li, S., Kim, A. S., DeFilipp, Z. M., El-Jawahri, A. R., McAfee, S. L., Brunner, A. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0182 · Cited by 55
Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia
Patel, K. P., Barkoh, B. A., Chen, Z., Ma, D., Reddy, N., Medeiros, L. J., & Luthra, R. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.06.004 · Cited by 55
Ravandi, F., Patel, K. P., Luthra, R., Faderl, S. H., Konopleva, M. Y., Kadia, T. M., Brandt, M., Pierce, S. A., Kornblau, S. M., Andreeff, M., et al. (2011) · Cancer · doi:10.1002/cncr.26580 · Cited by 55
Renneville, A., Abdelali, R. B., Chevret, S., Nibourel, O., Cheok, M. H.-C., Pautas, C., Duléry, R., Boyer, T., Cayuela, J., Hayette, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1536 · Cited by 55
Salipante, S. J., Fromm, J. R., Shendure, J., Wood, B. L., & Wu, D. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.57 · Cited by 55
What are we learning from the cancer genome?
Collisson, E. A., Cho, R. J., & Gray, J. W. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.159 · Cited by 55
Next Generation Sequencing of Acute Myeloid Leukemia: Influencing Prognosis
Ilyas, A. M., Ahmad, S., Faheem, M., Naseer, M. I., Kumosani, T., Al-Qahtani, M. H., Gari, M. A., & Ahmed, F. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s1-s5 · Cited by 55
Metabolic interactions with cancer epigenetics
Gao, X., Reid, M. A., Kong, M., & Locasale, J. W. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.09.001 · Cited by 55
Accumulation of DNA damage in the aged hematopoietic stem cell compartment
Beerman, I. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.11.001 · Cited by 55
Impact of somatic and germline mutations on the outcome of systemic mastocytosis
Muñoz‐González, J. I., Jara‐Acevedo, M., Álvarez‐Twöse, I., Merker, J. D., Teodósio, C., Hou, Y., Henriques, A., Roskin, K. M., Sánchez‐Muñoz, L., Tsai, A. G., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020628 · Cited by 55
The clinical use of IDH1 and IDH2 mutations in gliomas
Pïcca, A., Berzero, G., Stefano, A. L. D., & Sanson, M. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1548935 · Cited by 55
Gaster, M., Nehlin, J. O., & Minet, A. D. (2012) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.656653 · Cited by 55
Does massively parallel DNA resequencing signify the end of histopathology as we know it?
Aparicio, S. A. J. R., & Huntsman, D. D. (2009) · The Journal of Pathology · doi:10.1002/path.2636 · Cited by 55
Galante, P. A. F., Parmigiani, R. B., Zhao, Q., Caballero, O. L., de Souza, J. E., Navarro, F. C. P., Gerber, A. L., Nicolás, M., Salim, A. C. M., Silva, A. P. M., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr221 · Cited by 54
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia
Gallipoli, P., Giotopoulos, G., & Huntly, B. J. P. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715577614 · Cited by 53
Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow
Paubelle, É., Zylbersztejn, F., Maciel, T. T., Carvalho, C., Mupo, A., Cheok, M. H.-C., Lieben, L., Sujobert, P., Decroocq, J., Yokoyama, A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.055 · Cited by 53
Wakita, S., Yamaguchi, H., Ueki, T., Usuki, K., Kurosawa, S., Kobayashi, Y., Kawata, E., Tajika, K., Gomi, S., Koizumi, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.288 · Cited by 52
Yamaguchi, S., Iwanaga, E., Tokunaga, K., Nanri, T., Shimomura, T., Suzushima, H., Mitsuya, H., & Asou, N. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12271 · Cited by 52
Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications
Grossmann, V., Roller, A., Klein, H., Weißmann, S., Kern, W., Haferlach, C., Dugas, M., Haferlach, T., Schnittger, S., & Kohlmann, A. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.003 · Cited by 52
Proximity ligation assay evaluates IDH1R132H presentation in gliomas
Bunse, L., Schumacher, T., Sahm, F., Pusch, S., Oezen, I., Rauschenbach, K. J., Gonzalez, M., Solecki, G. M., Osswald, M., Capper, D., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77780 · Cited by 52
Glioma-derived mutations in IDH: From mechanism to potential therapy
Fu, Y., Huang, R., Du, J., Yang, R., An, N., & Liang, A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.05.115 · Cited by 52
Harada, Y., Nagata, Y., Kihara, R., Ishikawa, Y., Asou, N., Ohtake, S., Miyawaki, S., Sakura, T., Ozawa, Y., Usui, N., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.01.008 · Cited by 52
Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis
Pronier, E., Bowman, R. L., Ahn, J., Glass, J. L., Kandoth, C., Merlinsky, T. R., Whitfield, J. T., Durham, B. H., Gruet, A., Somasundara, A. V. H., et al. (2018) · Blood · doi:10.1182/blood-2018-03-837468 · Cited by 52
Functional significance of U2AF1 S34F mutations in lung adenocarcinomas
Esfahani, M. S., Lee, L. J., Jeon, Y.-J., Flynn, R. A., Stehr, H., Hui, A. B., Ishisoko, N., Kildebeck, E., Newman, A. M., Bratman, S. V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13392-y · Cited by 52
Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
Marvin‐Peek, J., Savani, B. N., Oluwole, O. O., & Dholaria, B. (2022) · Cancers · doi:10.3390/cancers14030497 · Cited by 52
Bioinformatics for cancer immunology and immunotherapy
Charoentong, P., Angelova, M., Efremova, M., Gallasch, R., Hackl, H., Galon, J., & Trajanoski, Z. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1354-x · Cited by 52
The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia
Owen, C., Fitzgibbon, J., & Paschka, P. (2009) · Hematological Oncology · doi:10.1002/hon.931 · Cited by 52
The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia
Tiacci, E., Grossmann, V., Martelli, M. P., Kohlmann, A., Haferlach, T., & Falini, B. (2011) · Haematologica · doi:10.3324/haematol.2011.057901 · Cited by 52
RNA modifications in hematopoietic malignancies: a new research frontier
Qing, Y., Su, R. J., & Chen, J. (2021) · Blood · doi:10.1182/blood.2019004263 · Cited by 51
Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group
Nomdedeu, J. F., Hoyos, M., Carricondo, M., Esteve, J., Bussaglia, E., Estivill, C., Ribera, J., Duarte, R. F., Salamero, O., Gallardo, D., et al. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.03.019 · Cited by 51
Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?
van Lith, S. A. M., Navis, A. C., Verrijp, K. N., Niclou, S. P., Bjerkvig, R., Wesseling, P., Tops, B. B. J., Molenaar, R. J., Noorden, C. J. F. V., & Leenders, W. P. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.004 · Cited by 51
Ofran, Y., & Rowe, J. M. (2012) · British Journal of Haematology · doi:10.1111/bjh.12135 · Cited by 51
TET proteins: on the frenetic hunt for new cytosine modifications
Delatte, B., & Fuks, F. (2013) · Briefings in Functional Genomics · doi:10.1093/bfgp/elt010 · Cited by 51
Auslander, N., Cunningham, C. E., Toosi, B. M., McEwen, E., Yizhak, K., Vizeacoumar, F. S., Parameswaran, S., Gonen, N., Freywald, T., Bhanumathy, K. K., et al. (2017) · Molecular Systems Biology · doi:10.15252/msb.20177739 · Cited by 51
DNA Methyltransferases in Hematologic Malignancies
Li, K. K., Luo, L., Shen, Y., Xu, J., Zhu, C. H., & Chen, S. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.01.005 · Cited by 50
Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions
Gilbert, A., Tudor, M., Montanari, J., Commenchail, K., Savu, D., Lesueur, P., & Chevalier, F. (2023) · Cancers · doi:10.3390/cancers15071962 · Cited by 51
Gene mutations and molecularly targeted therapies in acute myeloid leukemia.
Hatzimichael, E. C., Georgiou, G. K., Benetatos, L., & Briasoulis, E. C. (2013) · Europe PMC (PubMed Central) · Cited by 50
Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights
Ng, K., Kim, R., Kesari, S., Carter, B. S., & Chen, C. C. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0714-2 · Cited by 50
A panoramic view of acute myeloid leukemia
Chen, S., Shen, Y., & Chen, Z. (2013) · Nature Genetics · doi:10.1038/ng.2651 · Cited by 50
Weller, M., Wick, W., & von Deimling, A. (2011) · Glia · doi:10.1002/glia.21130 · Cited by 50
The biology and clinical impact of genetic lesions in myeloid malignancies
Lindsley, R. C., & Ebert, B. L. (2013) · Blood · doi:10.1182/blood-2013-06-460295 · Cited by 50
Sequencing and analysis of an Irish human genome
Tong, P., Prendergast, J. G. D., Lohan, A. J., Farrington, S. M., Cronin, S., Friel, N., Bradley, D. G., Hardiman, O. M., Evans, A. C. O., Wilson, J. F., et al. (2010) · Genome biology · doi:10.1186/gb-2010-11-9-r91 · Cited by 50
F11R Is a Novel Monocyte Prognostic Biomarker for Malignant Glioma
Pong, W. W., Walker, J., Wylie, T., Magrini, V. J., Luo, J. R., Emnett, R. J., Choi, J., Cooper, M. L., Griffith, M., Griffith, O. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077571 · Cited by 50
Self-citation
Metadata
- Authors
- Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., Fulton, L. A., Locke, D. P., Magrini, V. J., Abbott, R. M., Vickery, T. L., Reed, J. S., Robinson, J. S., Wylie, T., Smith, S. M., Carmichael, L., Eldred, J. M., Harris, C. C., Walker, J., Peck, J. B., Du, F., Dukes, A. F., Sanderson, G. E., Brummett, A. M., Clark, E., McMichael, J. F., Meyer, R. J., Schindler, J. K., Pohl, C. S., Wallis, J. W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M. E., Ivy, J. V., Kalicki, J., Elliott, G., Ries, R. E., Payton, J. E., Westervelt, P., Tomasson, M. H., Watson, M. A., Baty, J., Heath, S., Shannon, W. D., Nagarajan, R., Link, D. C., Walter, M. J., Graubert, T. A., DiPersio, J. F., Wilson, R. K., & Ley, T. J.
- Affiliations
- Washington University in St. Louis (US)
- Alvin J. Siteman Cancer Center (US)
- ORCID
- Mardis, Elaine R.
- Ding, Li
- Larson, David E.
- McLellan, Michael D.
- Chen, Ken
- Koboldt, Daniel C.
- Fulton, Robert S.
- McGrath, Sean D.
- Magrini, Vincent J.
- Vickery, Tammi L.
- Wylie, Todd
- Walker, Jason
- McMichael, Joshua F.
- Pohl, Craig S.
- Tang, Yuzhu
- Ries, Rhonda E.
- Payton, Jacqueline E.
- Tomasson, Michael H.
- Watson, Mark A.
- Heath, Sharon
- Link, Daniel C.
- Walter, Matthew J.
- Graubert, Timothy A.
- DiPersio, John F.
- Wilson, Richard K.
- Ley, Timothy J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1058-1066
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3201812
- OpenAlex
- W2134061682
- Cited by
- 2,219
- References
- 31
- Citations by year
- 2026: 35 · 2025: 44 · 2024: 57 · 2023: 76 · 2022: 81 · 2021: 107 · 2020: 104 · 2019: 115 · 2018: 120 · 2017: 126 · 2016: 136 · 2015: 154 · 2014: 163 · 2013: 197 · 2012: 251
- FWCI
- 154.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (U54HG003079)
- National Cancer Institute (P01CA101937)
- National Center for Research Resources (UL1RR024992)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- acute myeloid leukemia, somatic mutations, IDH1 mutation, NPM1 mutation, NRAS mutation, cytogenetically normal AML, tumor genome sequencing
- MeSH terms
- Nucleophosmin, Adult, DNA Mutational Analysis, Female, Gene Frequency, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Leukemia, Myeloid, Acute, Genome, Human, Point Mutation, Sequence Analysis, DNA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
